{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:32:37Z","timestamp":1771230757982,"version":"3.50.1"},"reference-count":125,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006041","name":"Innovate UK","doi-asserted-by":"publisher","award":["74442"],"award-info":[{"award-number":["74442"]}],"id":[{"id":"10.13039\/501100006041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bbrc.2023.08.021","type":"journal-article","created":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T11:11:02Z","timestamp":1692097862000},"page":"168-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection"],"prefix":"10.1016","volume":"677","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2846-6772","authenticated-orcid":false,"given":"Douglas","family":"Fraser-Pitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derry K.","family":"Mercer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4257-0162","authenticated-orcid":false,"given":"Marie-Louise","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Toledo-Aparicio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5890-0923","authenticated-orcid":false,"given":"Daniel W.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0004-0227","authenticated-orcid":false,"given":"Deborah A.","family":"O'Neil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.bbrc.2023.08.021_bib1","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13023-014-0189-2","article-title":"Cysteamine (Lynovex\u00ae), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis","volume":"30","author":"Charrier","year":"2014","journal-title":"Orphanet J. Rare Dis."},{"issue":"10","key":"10.1016\/j.bbrc.2023.08.021_bib2","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1128\/AAC.01198-16","article-title":"Activity of cysteamine against the cystic fibrosis pathogen burkholderia cepacia complex","volume":"60","author":"Fraser-Pitt","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2023.08.021_bib3","volume":"vol. 86","author":"Fraser-Pitt","year":"2018"},{"issue":"10","key":"10.1016\/j.bbrc.2023.08.021_bib4","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.3389\/fimmu.2019.03042","article-title":"Inhibition of transglutaminase 2 as a potential host-directed therapy against Mycobacterium tuberculosis","volume":"24","author":"Palucci","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib5","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/infdis\/174.1.214","article-title":"In vitro inhibition of the replication of human immunodeficiency virus type 1 by beta-mercaptoethylamine (cysteamine)","volume":"174","author":"Bergamini","year":"1996","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.bbrc.2023.08.021_bib6","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.bbrc.2017.05.172","article-title":"Metabolic pathway catalyzed by Vanin-1 pantetheinase plays a suppressive role in influenza virus replication in human alveolar epithelial A549 cells","volume":"489","author":"Yamashita","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bbrc.2023.08.021_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.exppara.2010.02.009","article-title":"Cysteamine, the natural metabolite of pantetheinase, shows specific activity against Plasmodium","volume":"125","author":"Min-Oo","year":"2010","journal-title":"Exp. Parasitol."},{"issue":"8","key":"10.1016\/j.bbrc.2023.08.021_bib8","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1128\/AAC.01719-09","article-title":"Cysteamine, the molecule used to treat cystinosis, potentiates the antimalarial efficacy of artemisinin","volume":"54","author":"Min-Oo","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/s12936-016-1317-3","article-title":"Cysteamine broadly improves the anti-plasmodial activity of artemisinins against murine blood stage and cerebral malaria","volume":"15","author":"Moradin","year":"2016","journal-title":"Malar. J."},{"issue":"16","key":"10.1016\/j.bbrc.2023.08.021_bib10","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.1128\/MCB.24.16.7214-7224.2004","article-title":"Vanin-1-\/- mice exhibit a glutathione-mediated tissue resistance to oxidative stress","volume":"24","author":"Berruyer","year":"2004","journal-title":"Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.bbrc.2023.08.021_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1172\/JCI200419557","article-title":"Vanin-1(-\/-) mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores","volume":"113","author":"Martin","year":"2004","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib12","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/ibd.21031","article-title":"Epithelial vanin-1 controls inflammation-driven carcinogenesis in the colitis-associated colon cancer model","volume":"16","author":"Pouyet","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"issue":"11","key":"10.1016\/j.bbrc.2023.08.021_bib13","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1097\/MIB.0b013e3182a32b03","article-title":"Functional polymorphisms in the regulatory regions of the VNN1 gene are associated with susceptibility to inflammatory bowel diseases","volume":"19","author":"Gensollen","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"issue":"12","key":"10.1016\/j.bbrc.2023.08.021_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242945","article-title":"Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: an exploratory randomized clinical trial","volume":"15","author":"Devereux","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bbrc.2023.08.021_bib15","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1042\/ETLS20200351","article-title":"What role for cysteamine in the defence against infection?","volume":"5","author":"Fraser-Pitt","year":"2021","journal-title":"Emerg. Top. Life Sci."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cells11010052","article-title":"Cysteamine with in vitro antiviral activity and immunomodulatory effects has the potential to Be a repurposing drug candidate for COVID-19 therapy","volume":"11","author":"Alonzi","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41420-022-01080-8","article-title":"Cysteamine exerts in vitro antiviral activity against the SARS-CoV-2 Delta and Omicron variants","volume":"8","author":"Alonzi","year":"2022","journal-title":"Cell Death Discov."},{"issue":"3","key":"10.1016\/j.bbrc.2023.08.021_bib18","doi-asserted-by":"crossref","first-page":"L372","DOI":"10.1152\/ajplung.00136.2022","article-title":"Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19","volume":"323","author":"Khanna","year":"2022","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"1\u20132","key":"10.1016\/j.bbrc.2023.08.021_bib19","first-page":"192","article-title":"In vitro activity of cysteamine against SARS-CoV-2 variants","volume":"137","author":"Thoene","year":"2020","journal-title":"Mol. Genet. Metabol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib20","series-title":"The Review on Antimicrobial Resistance","article-title":"Tackling drug-resistant infections globally: final report and recommendations","author":"O'Neill","year":"2016"},{"issue":"15","key":"10.1016\/j.bbrc.2023.08.021_bib21","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2119893119","article-title":"COVID-19 therapeutics: challenges and directions for the future","volume":"119","author":"Robinson","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"4","key":"10.1016\/j.bbrc.2023.08.021_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.tim.2016.01.009","article-title":"Sharing data for global infectious disease surveillance and outbreak detection","volume":"24","author":"Aarestrup","year":"2016","journal-title":"Trends Microbiol."},{"issue":"3","key":"10.1016\/j.bbrc.2023.08.021_bib23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/inthealth\/ihx012","article-title":"Global infectious disease surveillance: getting back to basics","volume":"9","year":"2017","journal-title":"Int. Health"},{"key":"10.1016\/j.bbrc.2023.08.021_bib24","article-title":"Pandemics- one health preparedness for the next","volume":"9","author":"Aarestrup","year":"2021","journal-title":"Lancet Reg. Health Eur."},{"issue":"8","key":"10.1016\/j.bbrc.2023.08.021_bib25","doi-asserted-by":"crossref","first-page":"954","DOI":"10.3390\/antibiotics10080954","article-title":"Paradigm shift in antimicrobial resistance pattern of bacterial isolates during the COVID-19 pandemic","volume":"10","author":"Saini","year":"2021","journal-title":"Antibiot. (Basel)"},{"issue":"11","key":"10.1016\/j.bbrc.2023.08.021_bib26","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac537","article-title":"A multicenter comparison of prevalence and predictors of antimicrobial resistance in hospitalized patients before and during the severe acute respiratory syndrome coronavirus 2 pandemic","volume":"9","author":"Bauer","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.bbrc.2023.08.021_bib27","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3181\/00379727-109-27169","article-title":"Clinical cure of herpes simplex keratitis by 5-iodo-2-deoxyuridine","volume":"109","author":"Kaufman","year":"1962","journal-title":"PSEBM (Proc. Soc. Exp. Biol. Med.)"},{"issue":"3","key":"10.1016\/j.bbrc.2023.08.021_bib28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1128\/CMR.00102-15","article-title":"Approved antiviral drugs over the past 50 years","volume":"29","author":"De Clercq","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"issue":"4","key":"10.1016\/j.bbrc.2023.08.021_bib29","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2019.1581171","article-title":"Broad-spectrum coronavirus antiviral drug discovery","volume":"14","author":"Totura","year":"2019","journal-title":"Expet Opin. Drug Discov."},{"issue":"6","key":"10.1016\/j.bbrc.2023.08.021_bib30","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1039\/D0CS01118E","article-title":"Antiviral drug discovery: preparing for the next pandemic","volume":"50","author":"Adamson","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"9","key":"10.1016\/j.bbrc.2023.08.021_bib31","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.2217\/imt.11.84","article-title":"Immunotherapeutic approaches against Staphylococcus aureus","volume":"3","author":"Verkaik","year":"2011","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bbrc.2023.08.021_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2014.04.004","article-title":"Immunotherapeutic interventions in chronic hepatitis B virus infection: a review","volume":"407","author":"Wang","year":"2014","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.bbrc.2023.08.021_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2123","article-title":"Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection","volume":"30","author":"Keam","year":"2020","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib34","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.3389\/fimmu.2020.02177","article-title":"Innate inspiration: antifungal peptides and other immunotherapeutics from the host immune response","volume":"11","author":"Mercer","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.mib.2020.09.007","article-title":"Immunotherapeutic approaches for fungal infections","volume":"58","author":"Williams","year":"2020","journal-title":"Curr. Opin. Microbiol."},{"issue":"5","key":"10.1016\/j.bbrc.2023.08.021_bib36","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1042\/ETLS20200348","article-title":"Antimicrobial immunotherapeutics: past, present and future","volume":"5","author":"Mercer","year":"2021","journal-title":"Emerg. Top. Life Sci."},{"key":"10.1016\/j.bbrc.2023.08.021_bib37","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1910993","article-title":"A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/17476348.2018.1401926","article-title":"Adherence and outcomes: a systematic review of palivizumab utilization","volume":"12","author":"Wong","year":"2018","journal-title":"Expet Rev. Respir. Med."},{"issue":"7","key":"10.1016\/j.bbrc.2023.08.021_bib39","doi-asserted-by":"crossref","first-page":"159","DOI":"10.21037\/atm.2017.03.69","article-title":"Alpha-interferon treatment in hepatitis B","volume":"5","author":"Woo","year":"2017","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib40","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/17425255.2018.1421173","article-title":"Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection","volume":"14","author":"Maughan","year":"2018","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"issue":"9","key":"10.1016\/j.bbrc.2023.08.021_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01061-20","article-title":"A randomized clinical trial of the efficacy and safety of interferon \u03b2-1a in treatment of severe COVID-19","volume":"64","author":"Davoudi-Monfared","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbrc.2023.08.021_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106903","article-title":"Interferon \u03b2-1b in treatment of severe COVID-19: a randomized clinical trial","volume":"88","author":"Rahmani","year":"2020","journal-title":"Int. Immunopharm."},{"issue":"12","key":"10.1016\/j.bbrc.2023.08.021_bib43","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s40261-021-01092-9","article-title":"Efficacy of interferon-\u03b2 in moderate-to-severe hospitalised cases of COVID-19: a systematic review and meta-analysis","volume":"41","author":"Kumar","year":"2021","journal-title":"Clin. Drug Invest."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib44","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","article-title":"Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Monk","year":"2021","journal-title":"Lancet Respir. Dis."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib45","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3947\/ic.2021.0028","article-title":"Effects of interferon beta in COVID-19 adult patients: systematic review","volume":"53","author":"Sosa","year":"2021","journal-title":"Infect. Chemother."},{"issue":"7","key":"10.1016\/j.bbrc.2023.08.021_bib46","doi-asserted-by":"crossref","first-page":"4102","DOI":"10.1002\/jmv.26976","article-title":"Interferon \u03b2-1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease","volume":"93","author":"Tortajada","year":"2021","journal-title":"J. Med. Virol."},{"issue":"5","key":"10.1016\/j.bbrc.2023.08.021_bib47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1080\/14787210.2022.2004118","article-title":"Clinical efficacy and safety of interferon-\u03b2-containing regimens in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"Chen","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"4","key":"10.1016\/j.bbrc.2023.08.021_bib48","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jmv.27475","article-title":"Study of the effects of interferon \u03b2-1a on hospitalized patients with COVID-19: SBMU Taskforce on the COVIFERON study","volume":"94","author":"Fallahzadeh","year":"2022","journal-title":"J. Med. Virol."},{"issue":"10339","key":"10.1016\/j.bbrc.2023.08.021_bib49","first-page":"1941","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2023.08.021_bib50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jgar.2020.12.011","article-title":"Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: preliminary observations","volume":"24","author":"Gaibani","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"issue":"12","key":"10.1016\/j.bbrc.2023.08.021_bib51","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","article-title":"Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.bbrc.2023.08.021_bib52","first-page":"672","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat. Med. (N. Y., NY, U. S.)"},{"issue":"Jan 19","key":"10.1016\/j.bbrc.2023.08.021_bib53","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"2022","author":"Fischer","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2023.08.021_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2021.108042","article-title":"Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease","volume":"110","author":"Macchiagodena","year":"2022","journal-title":"J. Mol. Graph. Model."},{"issue":"16","key":"10.1016\/j.bbrc.2023.08.021_bib55","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","author":"Gordon","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bbrc.2023.08.021_bib56","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1128\/JVI.02202-15","article-title":"Targeting innate immunity for antiviral therapy through small molecule agonists of the RLR pathway","volume":"90","author":"Pattabhi","year":"2015","journal-title":"J. Virol."},{"issue":"4","key":"10.1016\/j.bbrc.2023.08.021_bib57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/v10040211","article-title":"Gemcitabine and nucleos(t)ide synthesis inhibitors are broad-spectrum antiviral drugs that activate innate immunity","volume":"10","author":"Shin","year":"2018","journal-title":"Viruses. 20"},{"issue":"5","key":"10.1016\/j.bbrc.2023.08.021_bib58","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1099\/jgv.0.000758","article-title":"Broad-spectrum inhibition of common respiratory RNA viruses by a pyrimidine synthesis inhibitor with involvement of the host antiviral response","volume":"98","author":"Cheung","year":"2017","journal-title":"J. Gen. Virol."},{"issue":"10","key":"10.1016\/j.bbrc.2023.08.021_bib59","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00383-17","article-title":"Original chemical series of pyrimidine biosynthesis inhibitors that boost the antiviral interferon response","volume":"61","author":"Lucas-Hourani","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"issue":"3","key":"10.1016\/j.bbrc.2023.08.021_bib60","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/clim.1999.4777","article-title":"Mechanism of action for leflunomide in rheumatoid arthritis","volume":"93","author":"Fox","year":"1999","journal-title":"Clin. Immunol."},{"issue":"12","key":"10.1016\/j.bbrc.2023.08.021_bib61","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/15257770.2018.1508692","article-title":"Re-evaluation of Brequinar sodium, a dihydroorotate dehydrogenase inhibitor","volume":"37","author":"Peters","year":"2018","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"issue":"12","key":"10.1016\/j.bbrc.2023.08.021_bib62","first-page":"8247","article-title":"Brequinar inhibits enterovirus replication by targeting biosynthesis pathway of pyrimidines","volume":"12","author":"Fu","year":"2020","journal-title":"Am. J. Transl. Res."},{"issue":"6","key":"10.1016\/j.bbrc.2023.08.021_bib63","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.chembiol.2020.05.002","article-title":"Enhancing the antiviral efficacy of RNA-dependent RNA polymerase inhibition by combination with modulators of pyrimidine metabolism","volume":"27","author":"Liu","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"10","key":"10.1016\/j.bbrc.2023.08.021_bib64","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13238-020-00768-w","article-title":"Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2","volume":"11","author":"Xiong","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.bbrc.2023.08.021_bib65","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.927367","article-title":"Use of leflunomide as an antiviral agent with everolimus for BK virus nephropathy patients after kidney transplantation: a case series","volume":"21","author":"Yamazaki","year":"2020","journal-title":"Am. J. Case Rep."},{"issue":"7","key":"10.1016\/j.bbrc.2023.08.021_bib66","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0959-8049(05)80206-0","article-title":"Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients","volume":"29A","author":"de Forni","year":"1993","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbrc.2023.08.021_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107398","article-title":"Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: a comprehensive review","volume":"93","author":"Alamri","year":"2021","journal-title":"Int. Immunopharm."},{"issue":"3","key":"10.1016\/j.bbrc.2023.08.021_bib68","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/jmv.26512","article-title":"Methotrexate inhibits SARS-CoV-2 virus replication \"in vitro\"","volume":"93","author":"Caruso","year":"2020","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.bbrc.2023.08.021_bib69","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/v11040338","article-title":"Mechanism of action of methotrexate against Zika virus","volume":"11","author":"Beck","year":"2019","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.bbrc.2023.08.021_bib70","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/annrheumdis-2021-221916","article-title":"Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial","volume":"81","author":"Araujo","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bbrc.2023.08.021_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116936","article-title":"Part I. SARS-CoV-2 triggered 'PANIC' attack in severe COVID-19","volume":"415","author":"Frohman","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.bbrc.2023.08.021_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116935","article-title":"Part II. high-dose methotrexate with leucovorin rescue for severe COVID-19: an immune stabilization strategy for SARS-CoV-2 induced 'PANIC' attack","volume":"415","author":"Frohman","year":"2020","journal-title":"J. Neurol. Sci."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib73","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809528","article-title":"Identification and characterization of GLDC as host susceptibility gene to severe influenza","volume":"11","author":"Zhou","year":"2019","journal-title":"EMBO Mol. Med."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib74","first-page":"225","article-title":"Effects of the metabolites of the branched-chain amino acids and cysteamine on the glycine cleavage system","volume":"6","author":"Hayasaka","year":"1983","journal-title":"Biochem. Int."},{"issue":"3","key":"10.1016\/j.bbrc.2023.08.021_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000017","article-title":"IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo","volume":"4","author":"Sommereyns","year":"2008","journal-title":"PLoS Pathog."},{"issue":"11","key":"10.1016\/j.bbrc.2023.08.021_bib76","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1128\/JVI.00272-10","article-title":"Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections","volume":"84","author":"Mordstein","year":"2010","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib77","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib78","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.chom.2016.01.012","article-title":"SARS-CoV and IFN: too little, too late","volume":"19","author":"Kindler","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"6","key":"10.1016\/j.bbrc.2023.08.021_bib79","doi-asserted-by":"crossref","first-page":"L926","DOI":"10.1152\/ajplung.00374.2020","article-title":"Human coronaviruses 229E and OC43 replicate and induce distinct antiviral responses in differentiated primary human bronchial epithelial cells","volume":"319","author":"Loo","year":"2020","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108234","article-title":"Evasion of type I interferon by SARS-CoV-2","volume":"33","author":"Xia","year":"2020","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/infdis\/jiab147","article-title":"Human Rhinovirus infection blocks severe acute respiratory syndrome coronavirus 2 replication within the respiratory epithelium: implications for COVID-19 epidemiology","volume":"224","author":"Dee","year":"2021","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001091","article-title":"A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research","volume":"25","author":"Rihn","year":"2021","journal-title":"PLoS Biol."},{"issue":"1908","key":"10.1016\/j.bbrc.2023.08.021_bib83","first-page":"227","article-title":"The method of \u2018right and wrong cases\u2019 (\u2018constant stimuli\u2019) without Gauss's formulae","volume":"2","author":"Spearman","year":"1908","journal-title":"Br. J. Psychol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib84","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/BF01863914","article-title":"Beitrag zur kollektiven behandlung pharmakologiseher reihenversuche","volume":"162","author":"K\u00e4rber","year":"1931","journal-title":"Arch. Exp. Pathol. Pharmacol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib85","first-page":"493","article-title":"A simple method of estimating fifty-percent endpoints","volume":"27","author":"Reed","year":"1938","journal-title":"Am. J. Hyg."},{"key":"10.1016\/j.bbrc.2023.08.021_bib86","article-title":"Influenza: propagation, quantification, and storage","volume":"Chapter 15","author":"Szretter","year":"2006","journal-title":"Curr. Protoc. Microbiol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib87","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-59745-181-9_8","article-title":"Titration of human coronaviruses, HcoV-229E and HCoV-OC43, by an indirect immunoperoxidase assay","volume":"454","author":"Lambert","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib88","series-title":"Microbiology","first-page":"1044","article-title":"Nature of viruses","author":"Davis","year":"1972"},{"issue":"4","key":"10.1016\/j.bbrc.2023.08.021_bib89","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ymeth.2009.12.006","article-title":"Why the need for qPCR publication guidelines?--The case for MIQE","volume":"50","author":"Bustin","year":"2009","journal-title":"Methods"},{"issue":"6377","key":"10.1016\/j.bbrc.2023.08.021_bib90","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/357420a0","article-title":"Human aminopeptidase N is a receptor for human coronavirus 229E","volume":"357","author":"Yeager","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2023.08.021_bib91","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.51230","article-title":"The human coronavirus HCoV-229E S-protein structure and receptor binding","volume":"8","author":"Li","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.bbrc.2023.08.021_bib92","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.antiviral.2018.08.012","article-title":"Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses","volume":"158","author":"Luthra","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbrc.2023.08.021_bib93","doi-asserted-by":"crossref","DOI":"10.1186\/ar4444","article-title":"Methotrexate induces production of IL-1 and IL-6 in the monocytic cell line U937. 16(1):R17","author":"Olsen","year":"2014","journal-title":"Arthritis Res. Ther."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib94","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/01902140303768","article-title":"Methotrexate stimulates lung epithelial cells to release inflammatory cell chemotactic activities","volume":"29","author":"Koyama","year":"2003","journal-title":"Exp. Lung Res."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib95","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2131\/jts.39.319","article-title":"Involvement of epithelial-mesenchymal transition in methotrexate-induced pulmonary fibrosis","volume":"39","author":"Ohbayashi","year":"2014","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.bbrc.2023.08.021_bib96","article-title":"Cysteamine attenuate intestinal reperfusion injury induced by occlusion of mesenteric artery by enhancing intracellular thiol activities","author":"Alabi","year":"2022","journal-title":"Drug Res."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib97","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1194\/jlr.M088245","article-title":"Lysosomal oxidation of LDL alters lysosomal pH, induces senescence, and increases secretion of pro-inflammatory cytokines in human macrophages","volume":"60","author":"Ahmad","year":"2019","journal-title":"J. Lipid Res."},{"issue":"10","key":"10.1016\/j.bbrc.2023.08.021_bib98","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1093\/jas\/sky292","article-title":"Dietary cysteamine hydrochloride protects against oxidation, inflammation, and mucosal barrier disruption of broiler chickens challenged with Clostridium perfringens","volume":"96","author":"Liu","year":"2018","journal-title":"J. Anim. Sci."},{"key":"10.1016\/j.bbrc.2023.08.021_bib99","first-page":"3371","article-title":"Cysteamine suppresses human peripheral blood mononuclear cells--human corneal endothelial cell reaction via reactive oxygen species reduction","volume":"17","author":"Shin","year":"2011","journal-title":"Mol. Vis."},{"issue":"6","key":"10.1016\/j.bbrc.2023.08.021_bib100","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jpeds.2011.05.057","article-title":"Cysteamine toxicity in patients with cystinosis","volume":"159","author":"Besouw","year":"2011","journal-title":"J. Pediatr."},{"issue":"35","key":"10.1016\/j.bbrc.2023.08.021_bib101","doi-asserted-by":"crossref","first-page":"25189","DOI":"10.1074\/jbc.M703089200","article-title":"Discovery and characterization of a second mammalian thiol dioxygenase, cysteamine dioxygenase","volume":"282","author":"Dominy","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.bbrc.2023.08.021_bib102","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40261-016-0405-z","article-title":"An open-label investigation of the pharmacokinetics and tolerability of oral cysteamine in adults with cystic fibrosis","volume":"36","author":"Devereux","year":"2016","journal-title":"Clin. Drug Invest."},{"issue":"7","key":"10.1016\/j.bbrc.2023.08.021_bib103","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2183\/pjab.84.246","article-title":"Glycine cleavage system: reaction mechanism, physiological significance, and hyperglycinemia","volume":"84","author":"Kikuchi","year":"2008","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.bbrc.2023.08.021_bib104","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cell.2011.11.050","article-title":"Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis","volume":"148","author":"Zhang","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib105","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/toxsci\/63.1.57","article-title":"Mechanisms for the cytotoxicity of cysteamine","volume":"63","author":"Jeitner","year":"2001","journal-title":"Toxicol. Sci."},{"issue":"8","key":"10.1016\/j.bbrc.2023.08.021_bib106","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/v12080821","article-title":"Novel dihydroorotate dehydrogenase inhibitors with potent interferon-independent antiviral activity against Mammarenaviruses in vitro","volume":"12","author":"Kim","year":"2020","journal-title":"Viruses"},{"issue":"14","key":"10.1016\/j.bbrc.2023.08.021_bib107","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1073\/pnas.1101143108","article-title":"Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis","volume":"108","author":"Hoffmann","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"10","key":"10.1016\/j.bbrc.2023.08.021_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003678","article-title":"Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity","volume":"9","author":"Lucas-Hourani","year":"2013","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.bbrc.2023.08.021_bib109","first-page":"133","article-title":"Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis","volume":"15","author":"Alfaro-Lara","year":"2019","journal-title":"Rheumatol. Clin. (Engl. Ed.)"},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib110","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cyto.2005.12.009","article-title":"The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis","volume":"33","author":"Litinsky","year":"2006","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib111","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/aid.2005.0091","article-title":"Inhibition of HIV type 1 replication in CD4+ and CD14+ cells purified from HIV type 1-infected individuals by the 2-5A agonist immunomodulator, 2-5A(N6B)","volume":"23","author":"Dimitrova","year":"2007","journal-title":"AIDS Res. Hum. Retrovir."},{"issue":"6","key":"10.1016\/j.bbrc.2023.08.021_bib112","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s12250-020-00258-7","article-title":"A small-scale medication of leflunomide as a treatment of COVID-19 in an open-label blank-controlled clinical trial","volume":"35","author":"Hu","year":"2020","journal-title":"Virol. Sin."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib113","doi-asserted-by":"crossref","first-page":"127","DOI":"10.7326\/0003-4819-128-2-199801150-00009","article-title":"The pathophysiologic roles of interleukin-6 in human disease","volume":"128","author":"Papanicolaou","year":"1998","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.bbrc.2023.08.021_bib114","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1084\/jem.20101457","article-title":"Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice","volume":"208","author":"Oh","year":"2011","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2213-2600(20)30523-3","article-title":"Nebulised interferon beta-1a for patients with COVID-19","volume":"9","author":"Peiffer-Smadja","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.bbrc.2023.08.021_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antivir. Res."},{"issue":"5","key":"10.1016\/j.bbrc.2023.08.021_bib117","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S2213-2600(20)30566-X","article-title":"Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial","volume":"9","author":"Feld","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.bbrc.2023.08.021_bib118","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/j.ajpath.2020.07.001","article-title":"Association of initial viral load in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with outcome and symptoms","volume":"190","author":"Argyropoulos","year":"2020","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib119","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613422","article-title":"Interleukin-6 is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia","volume":"12","author":"Santa Cruz","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib120","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.718213","article-title":"Cysteamine inhibits Glycine utilisation and disrupts virulence in Pseudomonas aeruginosa","volume":"11","author":"Fraser-Pitt","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"10","key":"10.1016\/j.bbrc.2023.08.021_bib121","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ebiom.2015.08.018","article-title":"Cysteamine as a future intervention in cystic fibrosis against current and emerging pathogens: a patient-based ex vivo study confirming its antimicrobial and mucoactive potential in sputum","volume":"2","author":"Devereux","year":"2015","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.bbrc.2023.08.021_bib122","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1515\/pp-2017-0013","article-title":"Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an ex vivo and in vitro study","volume":"2","author":"Pillai","year":"2017","journal-title":"Pleura Peritoneum"},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib123","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1681\/ASN.2012090962","article-title":"Cysteamine modulates oxidative stress and blocks myofibroblast activity in CKD","volume":"25","author":"Okamura","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.bbrc.2023.08.021_bib124","doi-asserted-by":"crossref","first-page":"C73","DOI":"10.1152\/ajpcell.00110.2016","article-title":"Cigarette smoke-induced autophagy impairment accelerates lung aging, COPD-emphysema exacerbations and pathogenesis","volume":"314","author":"Vij","year":"2018","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.bbrc.2023.08.021_bib125","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.freeradbiomed.2018.11.023","article-title":"Autophagy augmentation alleviates cigarette smoke-induced CFTR-dysfunction, ceramide-accumulation and COPD-emphysema pathogenesis","volume":"131","author":"Bodas","year":"2019","journal-title":"Free Radic. Biol. Med."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23009592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X23009592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:33:40Z","timestamp":1757766820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X23009592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":125,"alternative-id":["S0006291X23009592"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.08.021","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cysteamine-mediated blockade of the glycine cleavage system modulates epithelial cell inflammatory and innate immune responses to viral infection","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2023.08.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 NovaBiotics Ltd. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}